Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis (Q33400570)

26 July 2017

title

Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis (English)

1 reference

3-[2-butyl-1-[2-(diethylamino)ethyl]-5-benzimidazolyl]-N-hydroxy-2-propenamide

26 July 2017

main subject

1 reference

ChEBI release 2020-05-28

1 reference

2

Hagop Kantarjian

1 reference

26 July 2017

3

Zeev Estrov

1 reference

26 July 2017

6

Srdan Verstovsek

1 reference

26 July 2017

5

Jorge Cortes

1 reference

26 July 2017

4

Gautam Borthakur

1 reference

26 July 2017

author name string

Alfonso Quintás-Cardama

series ordinal

1

1 reference

26 July 2017

publication date

2 April 2012

1 reference

26 July 2017

1 reference

26 July 2017

volume

36

1 reference

26 July 2017

issue

9

1 reference

26 July 2017

page(s)

1124-1127

1 reference

A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152772

JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152772

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152772

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152772

Identification of an acquired JAK2 mutation in polycythemia vera

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152772

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152772

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152772

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152772

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152772

The chronic myeloproliferative disorders: clonality and clinical heterogeneity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152772

JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152772

Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152772

The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152772

Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22475363

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22475363

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-T alpha chain expression

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22475363

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.LEUKRES.2012.03.003

1 reference

26 July 2017

1 reference

26 July 2017

1 reference